In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.
|Articles|April 23, 2015
Society for Clinical Research Sites Announces New Site Advocacy Groups
Author(s)Company Press Release
Advertisement
Ellicott City, M.D., April 22, 2015 – The
“The level of engagement seen from site and industry representatives with SCRS’ SAG initiative has exceeded even our most optimistic expectations,” states Christine Pierre, SCRS President. “Sites are able to provide direct feedback and see their knowledge and perspective embraced by industry leaders. The sites’ voice truly is being heard, and SCRS is pleased to announce additional opportunities for involvement in 2015.”
SCRS Circle of Sustainability Sponsor INC Research will launch two SAGs in 2015: Investigator Payment and Scientific and Operational. SCRS Site Engagement Partner Acurian will be launching the European Centralized Enrollment and Retention SAG.
SCRS is currently partnered with TransCelerate BioPharma Inc. on the Site Qualification and Training, Risk Based Monitoring, Investigator Registry, Shared Investigator Platform, and Common Protocol Template SAGs. SCRS is also in collaboration with Global Impact Partner Lilly for the Innovation SAG.
The opportunity to participate in a SAG is available to all SCRS members. To inquire about joining a SAG, please contact
Advertisement
Related to this article
Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5